2086 Results for "

hydroxy

" in MedChemExpress (MCE) Product Catalog:
Products (2086)

2086 Results for "hydroxy" in MCE Product Catalog:

Cat. No.: HY-E71859
Research Areas:  

Others

4-Hydroxysphinganine ceramide fatty acyl 2-hydroxylase (EC 1.14.18.6) is an oxidoreductase that can catalyze multiple reactions, including reaction 1: convert an N-(1,2 saturated acyl)-(4R)-hydroxysphinganine, 2 Fe(II)- [cytochrome b5], O2 and 2 H + into an N-(2R-hydroxyacyl)- 4R-hydroxysphinganine, 2 Fe(III)-[cytochrome b5] and H2O; reaction 2: convert an N-(1,2 saturated very-long-chain fatty acyl)-(R)-4-hydroxysphingoid base, 2 Fe(II)-[cytochrome b5], O2 and 2 H + into an N-(2R-hydroxy-very-long-chain fatty acyl)-(R)-4-hydroxysphingoid base, 2 Fe(III)-[cytochrome b5] and H2O.
loading...
    loading...
Cat. No.: HY-P811649
Synonyms: 8-hydroxy-2'-deoxyguanosine; 2'-Deoxy-8-oxoguanosine; 7,8-Dihydro-8-oxo-2'-deoxyguanosine; 8-Oxo-7,8-dihydro-2'-deoxyguanosine; 8-Oxo-7,8-dihydrodeoxyguanosine; 2'-Deoxy-8-oxo-D-guanosine; 8-Oxo-7,8-dihydro-2μ-deoxyguanosine,8-Oxo-dG; 2'-Deoxy-8-hydroxyguanosine;

Host:  

Mouse

Application:  

WB, IHC-P, IHC-F, ELISA, IF-Tissue, mIHC

Reactivity:  

Species independent

loading...
    loading...
Cat. No.: HY-16265A
CAS No.: 2514957-81-2
Research Areas:  

Cancer

JI-101 hydrochloride is an orally active angiogenesis inhibitor and anticancer agent with 55% oral bioavailability in Sprague Dawley rats, high permeability, and no P-gp substrate activity .JI-101 hydrochloride modulates angiogenesis signaling pathways in tumor vessel beds, downregulates EphB4, targets EphB4, VEGFR-2, and PDGFR-β, and inhibits multiple stages of tumor angiogenesis .JI-101 hydrochloride exerts activity against cancer cells and xenografts, exhibits mild to moderate inhibition of CYP3A4, and shows stability in pre-clinical and human liver microsomes .JI-101 hydrochloride undergoes rapid oral absorption in Sprague Dawley rats, has extensive tissue distribution with preferred lung uptake, and is excreted via bile with mono- and di-hydroxy metabolites, with feces as the primary elimination route .JI-101 hydrochloride can be used for the research of ovarian cancer and solid tumors .
loading...
    loading...
Cat. No.: HY-Y0148
CAS No.: 1679-53-4
Synonyms: NSC 15139; 10-HDAA
10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
loading...
    loading...
Cat. No.: HY-Y0148R
CAS No.: 1679-53-4
Synonyms: NSC 15139 (Standard); 10-HDAA (Standard)
10-Hydroxydecanoic acid (Standard) is the analytical standard of 10-Hydroxydecanoic acid. This product is intended for research and analytical applications. 10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells[1][2][3][4][5].
loading...
    loading...
Cat. No.: HY-L913
105 compounds

Recently, significant advancements in tyrosine-targeting electrophiles have primarily occurred in the field of protein-protein interactions (PPIs), where cysteine residues are often underrepresented and novel chemistries are needed to address these interfaces. In this context, tyrosines are frequently more accessible compared to more buried binding sites. Moreover, they are commonly found at "hot spots," which are functional epitopes of PPIs, with 12.3% of the residues consisting of tyrosines. This prevalence is likely due to the hydrophobic nature of tyrosine, its ability to participate in aromatic π-interactions, and its capacity for hydrogen bonding. Beyond PPIs, some progress has also been made in covalent tyrosine targeting in other areas where more commonly addressed side chains are lacking. Even though tyrosine has a slightly lower pKa value compared to the protonated lysine side chain (approximately 10 vs. 10.5 for the unprotected amino acid side chains), significantly less progress has been made in the development of tyrosine-targeted covalent ligands compared to lysine. This is likely due to the reduced flexibility of the tyrosine side chain and the greater steric hindrance of its hydroxy group, which makes it more challenging to adopt suitable reaction geometries.

Through careful selection, we constructed a structural filter containing over 110 electrophilic groups. By analyzing the electrophilic fragments selected by the structural filter, we removed any molecules with trivial or undesirable structural features. Ultimately, we obtained 124 fragment molecules which can target tyrosine residue and can be used for fragment-based covalent drug discovery.